Impact of target degradation on the 6FFF output of a Varian TrueBeam Linac.

The dosimetric output of a 6FFF beam, produced from a Varian TrueBeam linac exhibited an unexpected downward trend over time that was contrary to well-established expectations. To elucidate the cause of this uncharacteristic trend, a review of the linac's quality control results over its lifetime was performed, including, constancy checks of the dosimetric output, beam energy, flatness and symmetry, and percentage depth dose characteristics. These results were supplemented with a comprehensive series of measurements including flatness and symmetry measurements with a 1D-diode array, high-resolution measurements of the photon beam's build-up region with a parallel-plate chamber and measurement of the beam's output as a function of the x-ray target position. The review of the linac's QC results and supplemental tests identified no deviations in the linac's performance from its commissioning and baseline measurements. However, the 6FFF beam output exhibited a significant dependence on the target location relative to its default position, increasing by 5.43 % with a 0.5 mm target translation, indicating that target degradation was the cause of the atypical output trend. The change in output behaviour was believed to be the result of primary electrons escaping the degraded target and interacting with the linac's monitor chamber. Replacement of the x-ray target caused the 6FFF output to realign with expected trends. Target degradation was uncovered due to a robust quality control trending database and awareness of typical output behaviour. These results demonstrate the importance of data trending to identify component failure and provide centres with knowledge to recognise this potential fault.

GATE Monte Carlo approach to heterogeneity dose distribution in small fields used in radiation therapy.

The Accurate dosage prediction in Radiation Therapy is challenging, prompting a need for precision beyond conventional clinical Treatment Planning Systems (TPS). Monte Carlo-based methods are sought for their superior accuracy. The aim of this study is to compare dose distributions between the ACUROS algorithm and the GATE platform in various tissue densities and field sizes, focusing on smaller fields. This study was initiated with a homogeneous validation of the TrueBeam STX system, using measurements obtained from the Centre Hospitalier Interregional Edith Cavell (CHIREC) in Brussels. The validation compared dosimetric functions (Percentage Depth Dose (PDD), Dose profile (DP) and Collimator scatter fraction (CSF)) employing the GAMMA index with a 2% / 2 mm criterion tolerance. Following this, heterogeneous studies examined dose distributions between the ACUROS algorithm and the GATE platform in various tissue densities and field sizes, with a specific focus on smaller fields. Simulations were conducted using both platforms on chest phantoms with heterogeneous slabs representing bone, lung, and heart, each housing a central tumor. The impact of electronic equilibrium on tumors for different small field sizes was evaluated. Results showed a remarkable 99% agreement between measurements and GATE calculations in the homogeneous validation of the TrueBeam STX system. However, in heterogeneous studies, ACUROS consistently overestimated lung doses by up to 8% compared to GATE simulation, especially evident with a flattening filter and smaller beam sizes at density interfaces. This highlights significant dose estimation discrepancies between ACUROS and GATE, emphasizing the need for precise calculations. The findings support exploring Monte Carlo-based methods for enhanced accuracy in Radiation Therapy treatment planning.

Evaluating the Efficacy of Machine Performance Checks as an Alternative to Winston-Lutz Quality Assurance Testing in the TrueBeam Linear Accelerator with HyperArc.

HyperArc is a preferred technique for treating brain metastases, employing a single isocenter for multiple lesions. Geometrical isocentricity in the TrueBeam linear accelerator with HyperArc is crucial. We evaluated machine performance checks (MPCs) as an alternative to the Winston-Lutz (WL) test to verify the treatment isocenter. Between January and July 2023, we assessed 53 data points using MPC and Winston-Lutz tests. The isocenter size obtained from the MPC and its sum, including the rotation-induced couch shift, were compared with the maximum total delta value from the Winston-Lutz test. The maximum total delta was 0.68 ± 0.10 mm, while the isocenter size was 0.28 ± 0.02 mm. The sum of the isocenter size and rotation-induced couch shift measured by MPC was 0.61 ± 0.03 mm. During the Winston-Lutz test (without couch rotation), the maximum total delta value was 0.56 ± 0.13 mm. A t-test analysis revealed a significant difference in the isocenter size averages between the Winston-Lutz and MPC outcomes, whereas the Pearson's correlation coefficient yielded no correlation. Our study highlights the necessity for separate MPC and Winston-Lutz tests for isocenter verification. Therefore, the Winston-Lutz test should precede stereotactic radiosurgery for isocenter verification.

Particular issues to be considered in small field dosimetry for TrueBeam STx commissioning.

This study aims to report the relevant issues concerning small fields in the commissioning of a TrueBeam STx for photon energies of 6MV, 10MV, 6FFF, and 10FFF. Percent depth doses, profiles, and field output factors were measured according to the beam model configuration of the treatment planning system. Multiple detectors were used based on the IAEA TRS-483 protocol as well as EBT3 radiochromic film. Analytical Anisotropic and Acuros XB algorithms, were configured and validated through basic dosimetry comparisons and end-to-end clinical tests.

Application of a Comprehensive Treatment Planning Test for Credentialing Intensity-Modulated Radiotherapy and RapidArc in a TrueBeam Linear Accelerator Setup.

An extended version of task group report (TG)-119 dosimetric tests was introduced and tested on the TrueBeam linear accelerator setup. Treatment plan results and quality assurance (QA) results of RapidArc (RA) and intensity-modulated radiotherapy (IMRT) were compared to understand the limitation and efficacy of the RA and IMRT system of the linear accelerator. Test structure sets were drawn on OCTAVIUS four-dimensional (4D) phantom computed tomography scan data for this study. We generated treatment plans based on the specified goal in the Eclipse™ treatment planning system using RA and IMRT in the study phantom. We used the same planning objectives for RA and IMRT techniques. Planar dose verification was performed using electronic portal imaging device and OCTAVIUS 4D phantom. The treatment log file was further analyzed using Pylinac (V2.4.0 (Open Source Code library available on Github, runs under Python programming language)) to compare the dosimetric outcome of RA and IMRT. Dose to the planning target volume (PTV) 1-5 and organ at risk (OAR) were analyzed in this study for the efficiency comparison of RA and IMRT. The primary objective was accomplished by adhering to the dose constraints associated with PTV 2 and the OAR. RA and IMRT also met the secondary objective. The tertiary goal of dose delivery to PTV 4 was met with RA but not IMRT. This study can be utilized to compare different institutions' planning and patient-specific QA (PSQA) procedures. The findings of this study were in line with the published works of the literature. A multi-institutional planning and delivery accuracy audit can be built using this structure and set of planning objectives having similar PSQA phantom. The TG-119 report incorporated test challenges that were combined in a single study set and a single plan. This reduces the complexity of performing the original TG-119 tests, whereas keeping the challenges as introduced in the TG-119 report. This study's planning and dosimetric results could be further utilized for dosimetry audit with any institute having a linear accelerator and OCTAVIUS 4D phantom for PSQA.

Evaluation of the RadCalc collapsed cone dose calculation algorithm against measured data.

This work describes the experimental validation of the RadCalc (Lifeline software Inc, Tyler) collapsed cone dose calculation algorithm against measured data for a range of scenarios. 6 MV photon beam data were measured in a large water tank on a Varian TrueBeam linear accelerator. These were input into the RadCalc software, in conjunction with head geometry and output calibration information, then used to create a collapsed cone beam model. The model performance was assessed by comparison against measurement, using a selection of homogeneous and inhomogeneous geometries not incorporated into the original beam model. Dose calculations generated using the collapsed cone algorithm are generally in good agreement with measurement. However, the primary collimating of the linac is not accounted for in the RadCalc model and hence dose in the corners of large fields is significantly overestimated. Percentage depth doses were within 0.5% beyond a depth of 2 cm. The dose in the build-up region was underestimated by RadCalc Version 7.1.4.1, with (Distance To Agreement) discrepancies of up to 3 mm which were corrected in Version 7.2.2.0. Beam profiles for homogeneous phantom comparisons were within 2% in the central 80% of the field with out of field dose underestimated by no more than 3%. Dose comparisons in heterogeneous geometries were acceptable and generally within 3.5%. The largest observed differences were found at density interfaces and a result of the RadCalc dose resolution of 2 mm against 1 mm measured. Absolute dose comparisons demonstrated that RadCalc agreed with measurement to within 1.2% under homogeneous media irradiation geometries. For static beam IMRT deliveries agreement was within 2% or 2 mm of measured data, and for complex VMAT deliveries within 3% or 2 mm. The implementation of the (model-based) photon collapsed cone algorithm in RadCalc shows generally good agreement with measured data over a range of simple and complex scenarios considered.

The spatial accuracy of ring-mounted halcyon linac versus C-arm TrueBeam linac for single-isocenter/multi-target SBRT treatment.

Stereotactic body radiotherapy (SBRT) treatment of oligometastatic lesions via single-isocenter/multi-target (SIMT) plan is more efficient than using multi-isocenter/multitarget SBRT. This study quantifies the spatial positioning accuracy of 2 commercially available LINAC systems for SIMT treatment pertaining to the potential amplification of error as a function of the target's distance-to-isocenter. We compare the Ring-Gantry Halcyon LINAC equipped with the fast iterative conebeam-CT (iCBCT) for image-guided SIMT treatment, and the SBRT-dedicated C-Arm TrueBeam with standard pretreatment CBCT imaging. For both systems, Sun Nuclear's MultiMet Winston-Lutz Cube phantom with 6 metallic BBs distributed at different planes up to 7 cm away from the isocenter was used. The phantom was aligned and imaged via CBCT, and then couch corrections were applied. To treat all 6 BBs, an Eclipse 10-field 3D-conformal Field-in-Field (2×2 cm2 MLC field to each BB) plan for varying gantry, collimator, and couch (TrueBeam only) positions was developed for both machines with 6MV-FFF beam. The plan was delivered through ARIA once a week. The EPID images were analyzed via Sun Nuclear's software for spatial positioning accuracy. On TrueBeam, the treatment plan was delivered twice: once with 3DoF translational corrections and once with PerfectPitch 6DoF couch corrections. The average 3D spatial positioning accuracy was 0.55 ± 0.30 mm, 0.54 ± 0.24 mm, and 0.56 ± 0.28 mm at isocenter, and 0.59 ± 0.30 mm, 0.69 ± 0.30 mm, and 0.70 ± 0.35 mm at 7 cm distance-to-isocenter for Halcyon, TrueBeam 3DoF, and TrueBeam 6DoF, respectively. This suggests there are no clinically significant deviations of spatial uncertainty between the platforms with the distance-to-isocenter. On both platforms, our weekly independent measurements demonstrated the reproducibility for less than 1.0 mm positional accuracy of off-axis targets up to 7 cm from the isocenter. Due to this, no additional PTV-margin is suggested for lesions within 7 cm of isocenter. This study confirms that Halcyon can deliver similar positional accuracy to SBRT-dedicated TrueBeam to off-axis targets up to 7 cm from isocenter. These results further benchmark the spatial uncertainty of our extensively used SBRT-dedicated TrueBeam LINAC for SIMT SBRT treatments.

Volumetric modulated arc therapy for hippocampal-sparing prophylactic cranial irradiation: Planning comparison of Halcyon and C-arm accelerators.

Background: The purpose of the study was to evaluate the dosimetry of the Halcyon in prophylactic cranial irradiation (PCI) with volumetric modulated arc therapy (VMAT) and hippocampal-sparing for small cell lung cancer (SCLC). Methods: Five VMAT plans were designed on CT images of 15 patients diagnosed with SCLC and received PCI. Three plans with two full arcs were generated on the Trilogy and the TrueBeam accelerators, and flattening filter (FF) and flattening filter free (FFF) modes were used on TrueBeam. Two Halcyon plans with two and three full arcs were generated, referred to as H-2A and H-3A, respectively. The prescription dose was 25 Gy in 2.5-Gy fractions. The dose limit for hippocampus were D100 ≤ 9Gy and Dmax ≤ 16Gy. The Wilcoxon matched-paired signed-rank test was used to evaluate the significance of the observed differences between the five plans. Results: H-2A plans significantly increased the D2 of PTV, and H-3A plans showed comparable or even better target dosimetry (better conformity) compared to the three plans on C-arm accelerators. Compared to T and TB plans, the two Halcyon plans significantly reduced the D100 and mean doses of bilateral hippocampus, the mean doses of eyeballs, and the maximum doses of lenses. D100 of hippocampus was reduced in TrueBeam plans comparing to Trilogy plans. The FFF plans on TrueBeam also represented advantages in Dmean and D100 of hippocampas, Dmean and Dmax of eyeballs, and the Dmax of lenses compared to FF plans. Halcyon plans and TrueBeam plans with FFF mode increased the MUs compared to FF plans. Comparing to H-2A, the H-3A plans exhibited additional dosimetric advantages, including D2, CI and HI of PTV, as well as the maximum and mean doses of hippocampus and eyeballs, and the maximum doses of optic nerves and brainstem. The two Halcyon plans significantly reduced the delivery time and showed the higher gamma passing rate than the three plans of C-arm accelerators. Conclusions: Compared with the C-arm accelerators, the dose of hippocampus and the delivery times on Halcyon are relatively significantly reduced for hippocampal-sparing PCI. Three arcs are recommended for VMAT plans with the Halcyon in hippocampal-sparing PCI.

Evaluation of HyperArc™ using film and portal dosimetry quality assurance.

HyperArc™ is a stereotactic radiotherapy modality designed for targeting multiple brain metastases using a single isocenter with multiple non-coplanar arcs. This study aimed to assess the efficacy of two patient-specific quality assurance methods, film and the Varian Portal Dosimetry System with Varian's HyperArc™ technique and raise important considerations in the customisation of patient-specific quality assurance to accommodate HyperArc™ delivery. Assessment criteria included gamma analysis and mean dose at full width half maximum. The minimum metastasis size, maximum off-axis distance and suitable energy were identified and validated. Patient-specific quality assurance procedures were applied to a range of clinically relevant brain metastasis plans. Initial investigation into energy selection showed no significant differences in gamma pass rates using 6MV, 6MV FFF, or 10MV FFF for metastasis sizes greater than 15 mm diameter at the isocenter. Gamma pass rates (2%/2mm) for 15 mm metastases at the isocenter for all energies were greater than 96.0% for portal dosimetry and greater than 98.7% for film. Fields of size 15 mm placed at various distances (10-70 mm) from the isocenter resulted in a maximum mean dose difference of 1.5% between film and planned. Clinically relevant plans resulted in a maximum mean dose difference for selected metastases of 1.0% between film and plan and a maximum point dose difference of 2.9% between portal dose and plan. Portal dose image prediction was a quick and convenient quality assurance tool for metastases larger than 15 mm near the isocenter but provided diminished geometrical relevance for off-axis metastases. Film QA required exacting procedures but offered the ability to assess the accuracy of geometrical targeting for off-axis metastases and provided dosimetric accuracy for metastases to well below 15 mm diameter.

Patient specific evaluation of breathing motion induced interplay effects.

PURPOSE: In lung SABR, interplay between target motion and dynamically changing beam parameters can affect the target coverage. To identify the potential need for motion-management techniques, a comprehensive methodology for pre-treatment estimation of interplay effects has been implemented. METHODS: In conjunction with an alpha-version of VeriSoft and OCTAVIUS 4D (PTW-Freiburg, Germany), a method is presented to calculate a virtual, motion-simulated 3D dose distribution based on measurement data acquired in a stationary phantom and a subsequent correction with time-dependent target-motion patterns. In-house software has been developed to create user-defined motion patterns based on either simplistic or real patient-breathing patterns including the definition of the exact beam starting phase. The approach was validated by programmed couch and phantom motion during beam delivery. Five different breathing traces with extremely altered beam-on phases (0 % and 50 % respiratory phase) and a superior-inferior motion altitude of 25 mm were used to probe the influence of interplay effects for 14 lung SABR plans. Gamma analysis (2 %/2mm) was used for quantification. RESULTS: Validation measurements resulted in >98 % pass rates. Regarding the interplay effect evaluation, gamma pass rates of <92 % were observed for sinusoidal breathing patterns with <25 number of breaths per delivery time (NBs) and realistic patterns with <18 NBs. CONCLUSION: The potential influence of interplay effects on the target coverage is highly dependent on the patient's breathing behaviour. The presented moving-platform-free approach can be used for verification of ITV-based treatment plans to identify whether the clinical goals are achievable without explicit use of a respiratory management technique.

MLC performance prognosis using a degradation model based on trajectory log data from a daily test.

PURPOSE: This paper investigates the feasibility of implementing a predictive maintenance program for a multileaf collimator (MLC) based on data collected in trajectory logs (TLs) obtained by conducting a simple daily test, with the aim of minimizing unscheduled downtime. METHODS: A dynamic field test was designed, and the TLs generated in the course of daily administration in a linear accelerator were collected to evaluate trajectory deviations of the MLC leaves as well as interlocks (COL 420219/20, COL 420207/08) reported by the machine. During this evaluation, we observed that the trajectory deviations of some leaves increased up to a threshold value beyond which certain interlocks began to appear in treatment fields in those leaves. An exponential degradation model was therefore developed to predict this drift and determine each leaf's remaining useful life (RUL). Once the applicability of the model was confirmed, we added a second accelerator equipped with an MLC with the same configuration to validate the model. RESULTS: The model was able to predict certain COL 420219/20 interlocks resulting from primary readout/expected position discrepancies and to estimate each leaf's RUL. In total, 11 cases (8 interlocks + 3 potential interlocks avoided due to service interventions [27.3% of the total]) were detected over 7 days in advance, with no false positive results. Scheduling of service interventions several days prior to MLC failure would therefore be possible. When these types of interlocks were not predicted by the model, they were always generated by leaf motor failure. Consequently, intervention time could also be optimized by directly replacing the motor. During the study period, for these types of interlocks, our approach would have reduced downtime from 35.25 to 4.00 h (88.7%) and from 34.75 to 22.83 h (34.3%) for each accelerator, respectively. For COL 420207/08 interlocks, which are generated by primary/secondary readout discrepancies, no correlation with leaf trajectory deviation increases recorded in the TLs was found. Throughout the study period, these types of interlocks requiring service intervention, also mainly for motor replacement, represented a downtime of 9.50 h for the first accelerator (21.2% of total downtime) and by 4.33 h (11.1% of total downtime) for the second accelerator. CONCLUSION: This study demonstrates that by applying a predictive MLC maintenance program based on information collected in TLs, it is possible to predict certain interlocks and therefore schedule preemptive interventions to avoid their occurrence. This could optimize health-care delivery performance and minimize the loss of treatment sessions.

Varian eclipse stereotactic 5 mm cone data commissioning.

Conical collimators are effective and readily available accessories for the field shaping of small stereotactic fields, however the measurements required to accurately characterise the smallest radiation fields are difficult, prone to large errors, and there is little published commissioning data to compare measurements against. The aim of this investigation was to commission the cone dose calculation algorithm of a Varian Eclipse treatment planning system for a Varian 5 mm cone attached to a Varian TrueBeam linear accelerator beam-matched to the Varian Golden Beam Data (GBD). Tissue maximum ratios (TMRs) and off-axis ratios (OARs) were measured using PTW 60019 microDiamond and PTW 60018 SRS Diode detectors for a flattening filter free 6MV beam. The output factor (OF) was measured with the microDiamond and EBT-XD film. Results were compared to the GBD for this cone and an OF measured by the Australian Clinical Dosimetry Service during an independent audit. Film dosimetry was used to evaluate Eclipse dose calculations in a solid water phantom and end-to-end accuracy with an anthropomorphic head phantom. Output correction factors were derived from IAEA TRS-483. Gamma analysis was used to compare measured TMRs and OARs, and to compare Eclipse dose planes with film dosimetry results. Comparisons between measured and GBD TMRs passed gamma analysis within the specified criteria, while differences between distances to agreement for OARs measured with different detectors was attributed to different volume averaging characteristics. The OFs measured with the microDiamond and film agreed within measurement uncertainty. It was decided to configure Eclipse with the microDiamond measured OF and the SRS Diode measured TMR and OAR data. This was validated with various comparisons carried out to confirm both measurement accuracy and Eclipse configuration.

Comparison of MLC positioning deviations using log files and establishment of specific assessment parameters for different accelerators with IMRT and VMAT.

BACKGROUND AND PURPOSE: The study evaluated the differences in leaf positioning deviations by the log files of three advanced accelerators with two delivery techniques, and established specific assessment parameters of leaf positioning deviations for different types of accelerators. METHODS: A total of 420 treatment plans with 5 consecutive treatment log files were collected from the Trilogy, TrueBeam and Halcyon accelerators. Millennium MLC was equipped on the Trilogy and TrueBeam accelerators. A jawless design and dual-layer MLC were adopted on the Halcyon accelerator. 70 IMRT and 70 VMAT plans were selected randomly on each accelerator. The treatment sites of all plans included head and neck, chest, breast, pelvis and other sites. The parsing tasks for 2100 log files were proceeded by SunCheck software from Sun Nuclear Corporation. The maximum leaf root mean square (RMS) errors, 95th percentile errors and percentages of different leaf positioning errors were statistically analyzed. The correlations between these evaluation parameters and accelerator performance parameters (maximum leaf speed, mean leaf speed, gantry and arc angle) were analyzed. RESULTS: The average maximum leaf RMS errors of the Trilogy in the IMRT and VMAT plans were 0.44 ± 0.09 mm and 0.79 ± 0.07 mm, respectively, which were higher than the TrueBeam's 0.03 ± 0.01 mm, 0.03 ± 0.01 mm and the Halcyon's 0.05 ± 0.01 mm, 0.07 ± 0.01 mm. Similar data results were shown in the 95th percentile error. The maximum leaf RMS errors were strongly correlated with the 95th percentile errors (Pearson index > 0.5). The leaf positioning deviations in VMAT were higher than those in IMRT for all accelerators. In TrueBeam and Halcyon, leaf position errors above 1 mm were not found in IMRT and VMAT plans. The main influencing factor of leaf positioning deviation was the leaf speed, which has no strong correlation with gantry and arc angles. CONCLUSIONS: Compared with the quality assurance guidelines, the MLC positioning deviations tolerances of the three accelerators should be tightened. For both IMRT and VMAT techniques, the 95th percentile error and the maximum RMS error are suggested to be tightened to 1.5 and 1 mm respectively for the Trilogy accelerator. In TrueBeam and Halcyon accelerators, the 95th percentile error and maximum RMS error of 1 and 0.5 mm, respectively, are considered appropriate.

RapidPlan hippocampal sparing whole brain model version 2-how far can we reduce the dose?

Whole-brain radiotherapy has been the standard palliative treatment for patients with brain metastases due to its effectiveness, availability, and ease of administration. Recent clinical trials have shown that limiting radiation dose to the hippocampus is associated with decreased cognitive toxicity. In this study, we updated an existing Knowledge Based Planning model to further reduce dose to the hippocampus and improve other dosimetric plan quality characteristics. Forty-two clinical cases were contoured according to guidelines. A new dosimetric scorecard was created as an objective measure for plan quality. The new Hippocampal Sparing Whole Brain Version 2 (HSWBv2) model adopted a complex recursive training process and was validated with five additional cases. HSWBv2 treatment plans were generated on the Varian HalcyonTM and TrueBeamTM systems and compared against plans generated from the existing (HSWBv1) model released in 2016. On the HalcyonTM platform, 42 cases were re-planned. Hippocampal D100% from HSWBv2 and HSWBv1 models had an average dose of 5.75 Gy and 6.46 Gy, respectively (p < 0.001). HSWBv2 model also achieved a hippocampal Dmean of 7.49 Gy, vs 8.10 Gy in HSWBv1 model (p < 0.001). Hippocampal D0.03CC from HSWBv2 model was 9.86 Gy, in contrast to 10.57 Gy in HSWBv1 (p < 0.001). For PTV_3000, D98% and D2% from HSWBv2 model were 28.27 Gy and 31.81 Gy, respectively, compared to 28.08 Gy (p = 0.020) and 32.66 Gy from HSWBv1 (p < 0.001). Among several other dosimetric quality improvements, there was a significant reduction in PTV_3000 V105% from 35.35% (HSWBv1) to 6.44% (HSWBv2) (p < 0.001). On 5 additional validation cases, dosimetric improvements were also observed on TrueBeamTM. In comparison to published data, the HSWBv2 model achieved higher quality hippocampal avoidance whole brain radiation therapy treatment plans through further reductions in hippocampal dose while improving target coverage and dose conformity/homogeneity. HSWBv2 model is shared publicly.

A Comprehensive Evaluation of the Application of the Halcyon(2.0) IMRT Technique in Long-Course Radiotherapy for Rectal Cancer.

Objective: To evaluate if the Halcyon(2.0) Intensity Modulation Radiotherapy (IMRT) technique has an advantage in the long-course rectal cancer radiotherapy. Methods: A total of 20 clinical IMRT plans of Halcyon(2.0) for long-course (2Gy in 25 fractions) rectal cancer radiotherapy were randomly selected. Based on the parameters of these plans, 20 TrueBeam (with the Millennium 120 MLC) plans were redesigned, respectively. The dosimetry indexes, field complexity parameters, the Gamma Passing Rates (GPR), and the delivery time of the 2 groups of plans were obtained as measures of the plan quality, the modulation complexity, the delivery accuracy, and the delivery efficiency. The differences between the 2 groups of parameters were analyzed, with P < .05 means statistically significant. Results: In terms of dosimetry, there was no significant or clinical difference between the 2 groups in critical dosimetry parameters. The Monitor Unit of the Halcyon(2.0) fields is lower than the TrueBeam fields by 26.39, while the modulation complexity score (MCS), the mean aperture area variability (AAV), and the mean leaf sequence variability (LSV) of the Halcyon(2.0) fields were 23.8%, 20%, and 2.3% larger than those of the TrueBeam fields, respectively. Neither the ArcCheck-based GPRs nor the portal-dosimetry-based GPRs in both 3%/3 mm and 2%/2 mm criteria showed the difference between the Halcyon(2.0) fields and the TrueBeam fields. The Pearson correlation coefficient between GPR(2%/2 mm) and MCS of the Halcyon(2.0) fields was 0.335, while that of the TrueBeam fields was 0.502. The mean total delivery time of the TrueBeam plans was 195.55 ± 22.86 s, while that of Halcyon(2.0) was 124.25 ± 10.42 s (P < .001), which was reduced approximatively by 36%. Conclusion: For long-course rectal cancer radiotherapy, the Halcyon(2.0) IMRT plans behave almost the same in dosimetry and delivery accuracy as the TrueBeam plans. However, the lower MU and the field modulation complexity, combined with the higher delivery efficiency, make Halcyon(2.0) a feasible and reliable platform in long-course radiotherapy for the rectal cancer.

Interinstitutional beam model portability study in a mixed vendor environment.

A 6 MV flattened beam model for a Varian TrueBeamSTx c-arm treatment delivery system in RayStation, developed and validated at one institution, was implemented and validated at another institution. The only parameter value adjustments were to accommodate machine output at the second institution. Validation followed MPPG 5.a. recommendations, with particular attention paid to IMRT and VMAT deliveries. With this minimal adjustment, the model passed validation across a broad spectrum of treatment plans, measurement devices, and staff who created the test plans and executed the measurements. This work demonstrates the possibility of using a single template model in the same treatment planning system with matched machines in a mixed vendor environment.

Importance of Beam-Matching between TrueBeam STx and Novalis Tx in Pre-Treatment Quality Assurance Using Portal Dosimetry.

Flexibility and efficiency in a radiotherapy department with different linear accelerators (linacs) can be improved if they are dosimetrically equivalent, and there is no need of plan or patient-specific quality assurance (PSQA) modification. From 2012 to 2017, our institution purchased three Novalis Tx and one TrueBeam STx beam-matched accelerators with the same high-resolution multileaf collimator (MLC). They are matched taking as reference dosimetric data from Novalis Tx SN-5479. We showed the importance of beam-matched dosimetric units by the use of electronic portal image device (EPID) and Delta4 PSQA. It was able to treat patients on a different machine than the machine used for PSQA. Depth dose, beam profiles, output factors, dosimetric leaf gap, and MLC transmission were compared for all energies and linacs. PSQA in all linacs for 30 volumetric-modulated arc therapy plans was also compared. Prostate, breast, and head-and-neck cases were selected to consider low, middle, and high plan complexity, respectively. The comparisons were evaluated using EPID and Delta4 phantom. Dosimetric differences between the three Novalis Tx and TrueBeam STx in all energies were lower than 1%. The only significant difference was observed in Novalis EPID in middle complexity when the criterion was tighter in distance. This result could be related with the nonsymmetric dose delivery of semi arcs. In all other cases, there were no differences in two different EPID evaluations. However, TrueBeam EPID values were slightly higher than Novalis EPID values. This could be associated with the high-resolution novel diode detector TrueBeam EPID. The dosimetric data indicated that the Novalis Tx and TrueBeam STx are equivalent. PSQA using EPID and Delta4 phantom showed that there are no dosimetric differences in any of the linacs. These results revealed the flexibility performance in PSQA by beam-matching.

Technical note: GAMMORA, a free, open-source, and validated GATE-based model for Monte-Carlo simulations of the Varian TrueBeam.

PURPOSE: Monte Carlo (MC) is the reference computation method for medical physics. In radiotherapy, MC computations are necessary for some issues (such as assessing figures of merit, double checks, and dose conversions). A tool based on GATE is proposed to easily create full MC simulations of the Varian TrueBeam STx. METHODS: GAMMORA is a package that contains photon phase spaces as a pre-trained generative adversarial network (GAN) and the TrueBeam's full geometry. It allows users to easily create MC simulations for simple or complex radiotherapy plans such as VMAT. To validate the model, the characteristics of generated photons are first compared to those provided by Varian (IAEA format). Simulated data are also compared to measurements in water and heterogeneous media. Simulations of 8 SBRT plans are compared to measurements (in a phantom). Two examples of applications (a second check and interplay effect assessment) are presented. RESULTS: The simulated photons generated by the GAN have the same characteristics (energy, position, and direction) as the IAEA data. Computed dose distributions of simple cases (in water) and complex plans delivered in a phantom are compared to measurements, and the Gamma index (3%/3mm) was always superior to 98%. The feasibility of both clinical applications is shown. CONCLUSIONS: This model is now shared as a free and open-source tool that generates radiotherapy MC simulations. It has been validated and used for five years. Several applications can be envisaged for research and clinical purposes.

Reducing treatment machine downtime with a preventative MLC maintenance procedure.

The persistent use of MLCs through VMAT and IMRT is causing additional wear and tear on these mechanical parts, leading to an increase in MLC interlocks, breakdowns and failures. This study investigates the effect of an MLC clean and service procedure on MLC performance and positional accuracy demonstrated through in-house service logbook reports, Varian MLC backlash test results, daily MLC position QC results and Varian TrueBeam trajectory log file data. A service and clean of each individual MLC leaf was carried out on 3 standard MLC and 2 high definition MLC (HDMLC) Varian TrueBeam linacs. In-house service logbook reports, Varian backlash test results, daily MLC picket fence QC results and beam hold data from patient delivery trajectory log files were analysed for up to 6 months pre and 2 years post the MLC service/clean to assess the impact on unplanned MLC maintenance work and MLC performance. The median (range) of hardware faults reduced from 12 (1-17) pre clean to 0 (0-1) and 4 (1-11) at 12 and 24 months respectively for all linacs with the exception of a HDMLC linac where faults increased from 4 pre-clean to 13 and 20 again at 12 and 24 months respectively. The reduction in faults in the alternative 4 linacs was consistent with the reduction in the number of MLCs reaching the 0.3 mm and the 0.4 mm backlash recommendations in the first 12 and 24 months following the service/clean. The increase in faults in the HDMLC linac was also consistent with the increase in MLCs reaching the 0.3 mm backlash recommendation in the first 12 and 24 months. The median (range) of MLCs reaching a daily picket fence QC position tolerance of 0.25 mm reduced from 14 (1-40) pre clean to 0 (0) at both 12 and 24 months post-clean. This demonstrates the improvement in MLC performance caused by the MLC service/clean but also reveals factors other than MLC position accuracy influence hardware faults. Additionally, the number of beam hold-offs determined from patient delivery trajectory log files were found to have no correlation with the MLC service/clean. The MLC service/clean improves MLC performance and MLC position accuracy, reducing reactive repair work for engineering and physics staff. The results were maintained for 1 year post the MLC service/clean, with a trend back towards pre-clean levels in the subsequent 12-24 months. This suggests this preventative maintenance work could be performed at a frequency of > 2 years. This period of reduced faults and improved performance is significant given the 10 year expected lifespan of a linac.

Feasibility of spinal stereotactic body radiotherapy in Elekta Unity® MR-Linac.

The Elekta Unity MR-Linac (MRL) is expected to benefit spine stereotactic body radiotherapy (SBRT) due to the improved soft tissue contrast available with onboard MR imaging. However, the irradiation geometry and beam configuration of the MRL deviates from the conventional linear accelerator (Linac). The purpose of the study was to investigate the feasibility of spine SBRT on the MRL. Treatment plans were generated for lumbar and thoracic spines. Target and spinal cord doses were measured with two cylindrical ion chambers inserted into an anthropomorphic spine phantom. Our study indicated that the Monaco treatment planning system (TPS) could generate clinical treatment plans for the MRL that were of comparable quality to the RayStation TPS with a conventional Linac. For both Linacs the planned dose within the gross tumor volume agreed with measurements within ±3%. For the spinal cord, while the measured doses from the TrueBeam were 1.8% higher for the lumbar spine plan and 6.9% higher for thoracic spine plan, the measured doses from MRL were 0.6% lower for the lumbar spine plan and 3.9% higher for the thoracic spine plan. In conclusion, the feasibility of spine SBRT in Elekta Unity MRL has been demonstrated, however, more effort is needed for such as optimizing the online plan adaptation method.